Therapy for Menorrhagia and Dysfunctional Uterine Bleeding
For menorrhagia and dysfunctional uterine bleeding, the levonorgestrel-releasing intrauterine system (LNG-IUD) is the most effective medical therapy, reducing menstrual blood loss by 71-95% and achieving quality of life comparable to endometrial ablation. 1
First-Line Medical Management Algorithm
Initial Therapy Options (in order of effectiveness):
1. Levonorgestrel-Releasing IUD (20 μg/d)
- Most effective medical option with 71-95% reduction in menstrual blood loss 1
- Efficacy comparable to endometrial ablation 1
- Quality of life outcomes equivalent to hysterectomy 2
- Main effect is local at endometrial level with minimal systemic absorption 1
2. Combined Hormonal Contraceptives (CHCs)
- Reduce menstrual flow by approximately 50% 3
- Effective for both acute bleeding control and maintenance therapy 4
- For acute bleeding: multidose regimen can be used 4
3. Tranexamic Acid
- Most effective non-hormonal medical therapy 2
- Reduces bleeding by approximately 50% 3
- Critical caveat: Avoid in women with cardiovascular disease risk, history of MI, or thrombosis 1
4. NSAIDs
- Decrease bleeding by 30-50% 3
- Can be combined with hormonal methods for additive effect 4
- Treatment duration: 5-7 days 5
5. Oral Progestins (Cyclic)
- Reduce bleeding by 87% 1
- Often results in irregular bleeding or light menses only 1
- Particularly useful when estrogen is contraindicated 1
Management of Bleeding Irregularities
For Heavy or Prolonged Bleeding:
- First attempt: NSAIDs for 5-7 days 5
- If NSAIDs fail: Add hormonal treatment with COCs or estrogen for 10-20 days (if medically eligible) 5
- If bleeding persists or unacceptable: Counsel on alternative methods and offer different contraceptive/treatment option 5
For Acute Heavy Bleeding:
- Parenteral estrogen for hemodynamically unstable patients 4
- High-dose oral or injectable progestin-only medications for short-term control when bleeding not controlled 1
- Multidose combined oral contraceptive regimen 4
Second-Line Therapies
GnRH Agonists/Antagonists:
- Significantly reduce tumor volume and bleeding 6
- Primary use: Short-term preoperative preparation for surgery 6
- Major limitation: Hypoestrogenic effects (hot flushes, bone loss) limit long-term use 7
- Symptoms recur rapidly after discontinuation 7
Danazol:
- Effective but side effects make it unsuitable for long-term use 3
Surgical Options (When Medical Management Fails)
Hierarchy of surgical effectiveness (descending order):
- Hysterectomy - Most definitive, 90% patient satisfaction 7
- Endometrial Ablation (first or second generation) - Effective alternative to hysterectomy 2
- Hysteroscopic Myomectomy - For submucosal fibroids, especially if fertility desired 6
- Uterine Artery Embolization - 20-25% symptom recurrence at 5-7 years 7
Special Populations
Women on Anticoagulation:
- Preferred: Progestin-only methods 4
- Consider: LNG-IUD (levonorgestrel 20 μg/d) for bleeding control and pregnancy prevention 1
- Avoid: NSAIDs and tranexamic acid due to MI/thrombosis risk 1
- Among oral anticoagulants: Dabigatran has lower AUB risk than rivaroxaban/edoxaban; apixaban shows no significant difference vs warfarin 8
Women with Coagulopathies:
Women Desiring Fertility:
- Avoid: Endometrial ablation (high pregnancy complication risk) 6
- Avoid: Hysterectomy (permanent infertility) 6
- Preferred: Medical management or hysteroscopic myomectomy for structural lesions 6
Critical Clinical Pitfalls
Always evaluate for underlying pathology before initiating treatment - rule out pregnancy, structural lesions, malignancy, and coagulopathy 5
Age-specific endometrial biopsy requirements: Women ≥35 years with recurrent anovulation or <35 years with endometrial cancer risk factors require biopsy 9
Contraindications matter: Estrogen-containing therapies relatively contraindicated in women with cardiovascular disease (e.g., SCAD) 1
Reassess antiplatelet therapy: If patient on antiplatelet therapy develops heavy bleeding, first step is reassessing indication for ongoing therapy 1
Pregnancy counseling essential: All oral anticoagulants have teratogenic potential; ensure effective contraception or transition to safe agents (LMWH) if pregnancy desired 8